It was reported that MCP significantly reduced levels of fasting blood glucose, fasting blood insulin, total triglycerides, total cholesterol, low-density lipoprotein (LDL), and free-fatty acids, but increased the insulin sensitivity index, as well as levels of high-density lipoprotein (HDL) and adiponectin, indicating that MCPs improved glucose and lipid metabolism and may help control hyperglycemia in T2DM patients by downregulation of chronic inflammation and upregulation of and adiponectin production [167]. The gene discussed is INS; the disease is Hyperglycemia.